Focus: Caristo Diagnostics is a UK-based diagnostic company specializing in cardiac risk evaluation, focused on non-invasive cardiovascular assessment technologies. The company operates in the growing cardiac diagnostics segment but remains early-stage with limited public financial data.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Growing — net +14 jobs in 30d
14 jobs added vs 0 removed. Steady team buildout.
Caristo Diagnostics is a high-risk, early-stage diagnostic venture best suited for mission-driven researchers or entrepreneurs willing to accept significant uncertainty about funding, growth trajectory, and long-term viability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Caristo Diagnostics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Caristo Diagnostics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles